Sponsor: AVEO Pharmaceuticals, Inc.
Sponsor Study ID: AV-380-22-102
Study Title: A Phase 1 Dose Escalation Study of AV-380 in Combination with Standard of Care Chemotherapy in Metastatic Cancer Patients with Cachexia and Elevated GDF-15 Levels
CTO #: 103743
NCT Number: NCT05865535
Phase: I
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Colon; Pancreas
Study Objectives: To refine the dose and schedule of AV-380 and establish its adverse event (AE), pharmacokinetic (PK), and pharmacodynamic (PD) profile in metastatic cancer patients with cachexia and elevated GDF-15, receiving SoC chemotherapy for metastatic cancer